LA JOLLA, Calif., Dec. 9, 2021 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced
it will be hosting a live webcast investor and analyst day event
titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.
Volume 3 Highlights:
- AOC 1020 named as clinical development candidate for
Facioscapulohumeral Muscular Dystrophy (FSHD) program. AOC 1020
is now entering IND-enabling studies.
- Avidity anticipates three programs in clinical development
by the end of 2022. Clinical trial initiations for AOC 1020 and
AOC 1044, Avidity's lead program for Duchenne Muscular Dystrophy
(DMD) targeting Exon 44, are anticipated by the end of 2022.
- AOC 1001 MARINA study in adults with myotonic dystrophy
(DM1) is ongoing and continues to enroll patients. Avidity is
on track to conduct a preliminary assessment of safety,
tolerability and key biomarkers in approximately half of the study
participants in the Phase 1/2 MARINA trial in the fourth quarter of
2022.
"It is well known that the inappropriate expression of DUX4 is
the underlying cause of FSHD but before now, the technology didn't
exist to target it directly. Our AOC platform, combined with our
expertise in skeletal muscle diseases, enabled us to design AOC
1020 to directly target DUX4 and reduce its expression," said W.
Michael Flanagan, Ph.D., chief
technical officer. "We are grateful to have Dr. Jeffrey Statland join today to give a clinical
perspective of FSHD and to share the scientific and research
advancements being made to better understand this progressive and
debilitating disease with no treatment options."
Today's Video Webcast Information
A live video webcast of today's event will be available on the
Avidity website at
https://aviditybiosciences.investorroom.com/events-and-presentations
commencing 8:00 am PT / 11:00am ET. Following the event, a replay will be
archived on Avidity's website.
Avidity's management team will be joined by Jeffrey M. Statland, M.D., one of the principal
investigators for the multiple clinical studies in FSHD, including
the ongoing Motor Outcomes to Validate Evaluations in FSHD (MOVE
FSHD) study and its sub-study, MOVE Plus (MOVE+) being run by the
FSHD Clinical Trial Research Network. Dr. Statland is a Professor
of Neurology at the University of Kansas
Medical Center in Kansas City,
Kansas.
About Avidity Biosciences
Avidity Biosciences, Inc.'s mission is to profoundly improve
people's lives by delivering a new class of RNA therapeutics -
Antibody Oligonucleotide Conjugates (AOCs™). Avidity's
proprietary AOCs are designed to combine the specificity of
monoclonal antibodies with the precision of oligonucleotide
therapies to target the root cause of diseases previously
untreatable with RNA therapeutics. Avidity is on track to have
three programs in clinical development by the end of 2022. The
company's lead product candidate, AOC 1001, is designed to treat
patients with myotonic dystrophy type 1 (DM1). AOC 1001 has
commenced clinical testing with the ongoing Phase 1/2
MARINA™ trial in adults with DM1. The next programs in
the company's advancing and expanding pipeline are AOC 1044, the
lead of three programs for the treatment of DMD, and AOC 1020,
designed to treat people living with FSHD. Avidity anticipates both
programs will enter the clinic by the end of 2022. Avidity is
also broadening the reach of AOCs beyond muscle tissues through
both internal discovery efforts and key partnerships as the company
continues to deliver on the RNA revolution. Avidity is
headquartered in La Jolla, CA. For more information about
our science, pipeline and people, please
visit www.aviditybiosciences.com and engage with us
on LinkedIn and Twitter.
Forward-Looking Statements
Avidity cautions readers that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company's current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding:
the potential to develop a meaningful pipeline of novel AOC
therapeutics; the potential clinical development of AOC 1001 in
patients with DM1 and the expected timing of preliminary data from
the MARINA trial; the progression of clinical programs for AOC 1044
and AOC 1020 and timing of planned IND-enabling studies and
clinical trials; and the broad potential of AOCs to treat rare and
serious diseases. The inclusion of forward-looking statements
should not be regarded as a representation by Avidity that any of
these plans will be achieved. Actual results may differ from those
set forth in this press release due to the risks and uncertainties
inherent in the business, including, without limitation: Avidity is
early in its development efforts; Avidity's approach to the
discovery and development of product candidates based on its AOC
platform is unproven, and the company does not know whether it will
be able to develop any products of commercial value; potential
delays in the commencement, enrollment and completion of clinical
trials; disruption to its operations from the COVID-19
pandemic; the success of its preclinical studies and clinical
trials for the company's product candidates; the results of
preclinical studies and early clinical trials are not necessarily
predictive of future results; Avidity's dependence on third parties
in connection with preclinical testing and product manufacturing;
unexpected adverse side effects or inadequate efficacy of its
product candidates that may limit their development, regulatory
approval and/or commercialization, or may result in recalls or
product liability claims; and other risks described in prior press
releases and in filings with the Securities and Exchange Commission
(SEC). Avidity cautions readers not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and the company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Contacts:
Kathleen Gallagher
(858) 401-7900
kath.gallagher@aviditybio.com
Media Contact:
Cherise Adkins
cadkins@spectrumscience.com
(301) 267-4161
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-highlights-fshd-program-at-virtual-investor-and-analyst-event-301440804.html
SOURCE Avidity Biosciences, Inc.